Skip to main content

Advertisement

SpringerLink
Log in

Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature

  • PATHOGENESIS AND THERAPY IN AUTOIMMUNE DISEASES
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

In the present study, we performed a retrospective study on the indication, efficacy and causes of withdrawal of mycophenolate mofetil (MMF) in patients with systemic lupus erythematosus (SLE). Moreover, a review of the literature concerning the use of MMF in the real life was performed. We recorded data about indications, mean dosage, duration of treatment and reasons for drug withdrawal. The efficacy was evaluated according to changes in SLE Disease Activity Index 2000 (SLEDAI-2K), renal SLEDAI-2K and daily proteinuria, after 4 and 12 months of treatment. Six hundred and nine SLE patients were evaluated; among them, 109 patients (17.9 %) were treated with MMF (mean treatment duration 33.9 ± 31.2 months, mean dosage 28.1 ± 10.6 mg/kg). The most frequent indications for using MMF were lupus nephritis (55.9 %) and musculoskeletal manifestations (33.0 %). After 4 and 12 months, a significant reduction of mean SLEDAI-2K, renal SLEDAI and daily proteinuria, compared with baseline, was demonstrated. Thirty-one patients (28.4 %) discontinued MMF therapy (mean treatment duration at the time of discontinuation 17.5 ± 21.2 months). The incidence risks of MMF discontinuation due to inefficacy and side effects were 0.09 and 0.1, respectively. Patients with disease duration longer than 36 months (70.6 %) had a significant increased risk of MMF withdrawal (RR 0.4, P = 0.03). The results of the present study demonstrated that MMF should be considered a treatment option for SLE manifestation other than renal involvement in daily clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today. 2009;45:521–32.

    CAS  PubMed  Google Scholar 

  2. Dall’Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2011;23:454–8.

    Article  PubMed  Google Scholar 

  3. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.

    Article  CAS  PubMed  Google Scholar 

  4. Perricone C, Ciccacci C, Ceccarelli F, et al. TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. Immunogenetics. 2013;65:703–9.

    Article  CAS  PubMed  Google Scholar 

  5. Alessandri C, Barbati C, Vacirca D, et al. T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J. 2012;26:4722–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Colasanti T, Maselli A, Conti F, et al. Autoantibodies to estrogen receptor α interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2012;64:778–87.

    Article  CAS  PubMed  Google Scholar 

  7. Conti F, Alessandri C, Bompane D, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther. 2004;6:R366–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Cervera R, Doria A, Amoura Z, et al. Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev. 2014;13:621–9.

    Article  CAS  PubMed  Google Scholar 

  9. Conti F, Alessandri C, Perricone C, et al. Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One. 2012;7:e33824.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Italian Society of Rheumatology, Govoni M, Bombardieri S, Bortoluzzi A, et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford). 2012;51:157–68.

    Article  Google Scholar 

  11. Valesini G, Conti F. The persistent challenge of lupus nephritis. Clin Rev Immunol. 2011;40:135–7.

    Google Scholar 

  12. Conti F, Ceccarelli F, Perricone C, et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS One. 2012;7:e45934.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Conti F, Priori R, Alessandri C, et al. Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A. Lupus. 2000;9:676–80.

    Article  CAS  PubMed  Google Scholar 

  14. Conti F, Ceccarelli F, Perricone C, et al. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1148–52.

    Article  CAS  Google Scholar 

  15. Doria A, Gatto M, Zen M, et al. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev. 2014;13:770–7.

    Article  CAS  PubMed  Google Scholar 

  16. Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38:69–78.

    Article  CAS  PubMed  Google Scholar 

  17. Hong Kong Nephrology Study Group, Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076–84.

    Article  Google Scholar 

  18. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005;10:504–10.

    Article  CAS  Google Scholar 

  19. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219–28.

    Article  CAS  PubMed  Google Scholar 

  20. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971–80.

    Article  CAS  PubMed  Google Scholar 

  21. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Houssiau F, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis trial. Ann Rheum Dis. 2010;69:2083–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Riskalla MM, Somers EC, Fatica RA, et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1508–12.

    CAS  PubMed  Google Scholar 

  24. Pisoni CN, Sanchez FJ, Karim Y, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol. 2005;32:1047–52.

    CAS  PubMed  Google Scholar 

  25. Nannini C, Crowson CS, Matteson EL, et al. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study. Lupus. 2009;18:394–9.

    Article  CAS  PubMed  Google Scholar 

  26. Lourdudoss C. Vollenhoven Rv. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lupus. 2014;23:299–304.

    Article  CAS  PubMed  Google Scholar 

  27. Ginzler EM, Wofsy D, Isenberg D, et al. ALMS Group. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010;62:211–21.

    Article  CAS  PubMed  Google Scholar 

  28. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.

    Article  CAS  PubMed  Google Scholar 

  29. Pengo V, Tripodi A, Reber G, et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7:1737–40.

    Article  CAS  PubMed  Google Scholar 

  30. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2000;29:288–91.

    Google Scholar 

  31. Pitashny M, Schwartz N, Qing X, et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum. 2007;56:1894–903.

    Article  CAS  PubMed  Google Scholar 

  32. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–50.

    Article  PubMed  Google Scholar 

  33. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.

    Google Scholar 

  34. Borchers AT, Leibushor N, Naguwa SM, et al. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12:174–94.

    Article  PubMed  Google Scholar 

  35. Iaccarino L, Rampudda M, Canova M, et al. Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev. 2007;6:190–5.

    Article  CAS  PubMed  Google Scholar 

  36. Østensen M, Villiger PM, Förger F. Interaction of pregnancy and autoimmune rheumatic disease. Autoimmun Rev. 2012;11:A437–46.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lupus Clinic, Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy

    Fabrizio Conti, Fulvia Ceccarelli, Carlo Perricone, Laura Massaro, Enrica Cipriano, Viviana Antonella Pacucci, Simona Truglia, Francesca Miranda, Francesca Morello, Cristiano Alessandri, Francesca Romana Spinelli & Guido Valesini

Authors
  1. Fabrizio Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fulvia Ceccarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlo Perricone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laura Massaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Enrica Cipriano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Viviana Antonella Pacucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Simona Truglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francesca Miranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Francesca Morello
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cristiano Alessandri
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Francesca Romana Spinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Guido Valesini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Perricone.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Conti, F., Ceccarelli, F., Perricone, C. et al. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. Immunol Res 60, 270–276 (2014). https://doi.org/10.1007/s12026-014-8609-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-014-8609-x

Keywords

Search

Navigation